At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
VERA Vera Therapeutics, Inc.
Trading 11-22 10:30:18 EST
48.41
+1.38
+2.93%
High48.57
Low47.13
Vol50.85K
Open47.28
D1 Closing47.03
Amplitude3.06%
Mkt Cap3.07B
Tradable Cap2.29B
Total Shares63.32M
T/O2.44M
T/O Rate0.11%
Tradable Shares47.35M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Vera Therapeutics Initiated at Overweight by Wells Fargo
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.